View Older Stories View More Recent Stories

Aug 6, 2024 05:01PM Emergent BioSolutions Reports Second Quarter 2024 Financial Results
May 1, 2024 04:57PM Emergent BioSolutions Reports First Quarter 2024 Financial Results
Mar 6, 2024 04:31PM Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Mar 6, 2024 04:31PM Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results
Feb 29, 2024 07:00AM Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
Feb 29, 2024 07:00AM Emergent BioSolutions to Release Fourth Quarter & Full Year 2023 Financial Results, and Conduct Conference Call on March 6, 2024
Feb 21, 2024 07:03AM Emergent BioSolutions (EBS) Appoints Industry Leader Joseph C. Papa as New President and CEO
Feb 21, 2024 07:00AM Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
Jan 11, 2024 08:00AM Emergent BioSolutions (EBS) Wins $235.8M Contract to Supply BioThrax to US DoD
Jan 11, 2024 08:00AM Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
Jan 9, 2024 07:30AM Emergent BioSolutions to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 11, 2024
Nov 28, 2023 06:59AM Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
Nov 24, 2023 07:30AM Emergent BioSolutions (EBS) Receives NYSE Notice Regarding Delayed Form 10-Q Filing
Nov 24, 2023 07:30AM Emergent BioSolutions Receives NYSE Notice Regarding Delayed Form 10-Q Filing
Nov 8, 2023 05:38PM Emergent BioSolutions Reports Third Quarter 2023 Financial Results
Oct 30, 2023 04:45PM UPDATE: Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 8, 2023
Oct 19, 2023 06:30AM Emergent BioSolutions to Release Third Quarter 2023 Financial Results and Conduct Conference Call on November 2, 2023
Oct 16, 2023 07:00AM Emergent BioSolutions Partners with Emmitt Smith to Launch Ready to Rescue Campaign to Help Save Lives Amidst Rising Opioid Epidemic
Oct 2, 2023 07:00AM Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
Aug 30, 2023 05:59AM Emergent BioSolutions' (EBS) NARCAN Nasal Spray Launches Over the Counter
Aug 30, 2023 05:59AM Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
Aug 8, 2023 04:31PM Emergent BioSolutions Reports Financial Results for Second Quarter 2023
Aug 8, 2023 07:16AM Emergent BioSolutions (EBS) Announces Strategic Steps to Strengthen Core Business and Financial Position
Aug 8, 2023 07:15AM Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
Jul 31, 2023 04:08PM Emergent BioSolutions (EBS) Awarded 10-Year BARDA Contract Valued at up to $704M
Jul 31, 2023 04:05PM Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
Jul 25, 2023 06:30AM Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
Jul 21, 2023 05:41AM Emergent BioSolutions (EBS) Receives FDA Approval for CYFENDUS
Jul 20, 2023 06:03PM Emergent BioSolutions Receives U.S. FDA Approval of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted), previously known as AV7909, a Two-Dose Anthrax Vaccine for Post-Exposure Prophylaxis Use
May 15, 2023 07:58AM Emergent BioSolutions Finalizes Sale of Travel Health Business to Bavarian Nordic
May 11, 2023 06:30AM Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
May 11, 2023 06:30AM Emergent BioSolutions to Hold Virtual Annual Meeting of Stockholders on Thursday, May 25, 2023 at 9:00am EDT
May 9, 2023 04:05PM Emergent BioSolutions Reports Financial Results For First Quarter 2023
Apr 19, 2023 04:05PM Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
Apr 19, 2023 04:05PM Emergent BioSolutions to Release First Quarter 2023 Financial Results and Conduct Conference Call on May 9, 2023
Mar 29, 2023 09:49AM Emergent BioSolutions (EBS) Confirms U.S. FDA Approves Over-the-Counter Designation for NARCAN Nasal Spray
Mar 29, 2023 09:48AM U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
Mar 29, 2023 09:48AM U.S. FDA Approves Over-the-Counter Designation for Emergent BioSolutions’ NARCAN® Nasal Spray, a Historic Milestone for the Opioid Overdose Emergency Treatment
Feb 27, 2023 04:42PM Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
Feb 27, 2023 04:42PM Emergent BioSolutions Reports Financial Results for Fourth Quarter 2022
Feb 15, 2023 05:29PM Emergent BioSolutions (EBS) confirms FDA AdComm votes in favor of OTC NARCAN
Feb 15, 2023 05:19PM Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
Feb 15, 2023 05:19PM Emergent BioSolutions Reports FDA Advisory Committees’ Unanimous Vote in Favor of NARCAN® (naloxone HCI) Nasal Spray for Over-the-Counter Use
Feb 15, 2023 02:00AM Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
Feb 15, 2023 02:00AM Emergent BioSolutions Announces Sale of Travel Health Business to Bavarian Nordic for Up To $380 Million
Feb 6, 2023 04:05PM Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
Feb 6, 2023 04:05PM Emergent BioSolutions to Release Fourth Quarter 2022 Financial Results and Conduct Conference Call on February 27, 2023
Jan 9, 2023 06:59AM Emergent BioSolutions (EBS) Announces Organizational Changes
Jan 9, 2023 06:59AM Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
Jan 9, 2023 06:59AM Emergent BioSolutions Announces Organizational Changes as Part of Sharpened Strategic Focus
View More Recent Stories View Older Stories